P. P. Zvonar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
P. P. Zvonar has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Ihor Vakaliuk
Ivano-Frankivsk National Medical University
5 shared publications - Roksolana Denina
Department of Internal Medicine No. 2 and Nursing, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine
5 shared publications - Ihor Vandzhura
Department of Internal Medicine No. 2 and Nursing, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine
3 shared publications - Nestor Seredyuk
Ivano-Frankivsk national medical University, Department of internal medicine №2 and nursing, Ivano-Frankivsk, Ukraine
3 shared publications - Yaroslava Vandzhura
Department of Internal Medicine No. 2 and Nursing, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine
3 shared publications - D. A. Volynskyi
Ivano-Frankivsk National Medical University
2 shared publications
Latest Publications
- Open Access
- 8 July 2026
- Published by Zaporizhzhia State Medical and Pharmaceutical University in Zaporozhye Medical Journal
- Vol. 28 (4) , 301-308
A multimodal approach to heart failure of ischemic etiology with anemia and psychological distress
Iron deficiency and anemia are common comorbidities in patients with chronic heart failure (CHF) and are associated with reduced exercise tolerance, impaired quality of life, and poor prognosis. Depression and anxiety are also common and may further worsen clinical outcomes. Aim. To evaluate the dynamics of hematological and iron metabolism parameters in patients with chronic heart failure of ischemic etiology and iron deficiency anemia treated with intravenous ferric carboxymaltose (FCM), with special attention to the impact of concomitant depressive and anxiety symptoms. Materials and methods. A prospective observational study was conducted on 57 patients with CHF of ischemic etiology and laboratory-confirmed iron deficiency anemia. All patients received standard CHF therapy and intravenous FCM. Sertraline was added to 23 patients with clinically significant depressive and anxiety symptoms. Hematological parameters, iron parameters, quality of life and psychometric parameters (PHQ-9, GAD-7, SAQ) were assessed at baseline, day 160, and day 340. Results. Treatment resulted in significant improvements in hemoglobin, ferritin, transferrin saturation and red blood cell count in the cohort. In the subgroup with depressive/anxiety symptoms, improvements were more pronounced: hemoglobin levels increased from 111.6 (106.0; 126.4) g/L to 140.9 (125.7; 156.0) g/L at day 160 and 142.1 (128.5; 159.2) g/L at day 340, while ferritin levels increased from 52.7 (47.5; 59.0) μg/L to 103.8 (90.6; 111.0) μg/L and 116.0 (101.2; 123.9) μg/L, respectively. Depression and anxiety scores (PHQ-9, GAD-7) decreased significantly, which was accompanied by improvements in quality-of-life scores. Conclusions. Intravenous administration of FCM effectively corrects iron deficiency anemia in patients with CHF of ischemic etiology, resulting in sustained improvements in hematological and clinical parameters. Patients with comorbid depression and anxiety demonstrated more pronounced benefits, likely due to the combined effect of anemia correction and psychotropic support with sertraline. These results support a multidisciplinary approach that integrates cardiological and psychosocial care in the management of CHF.
- 8 July 2026
- Published by Zaporizhzhia State Medical and Pharmaceutical University in Zaporozhye Medical Journal
- Vol. 28 (4) , 301-308
Open AccessA multimodal approach to heart failure of ischemic etiology with anemia and psychological distress
Iron deficiency and anemia are common comorbidities in patients with chronic heart failure (CHF) and are associated with reduced exercise tolerance, impaired quality of life, and poor prognosis. Depression and anxiety are also common and may further worsen clinical outcomes. Aim. To evaluate the dynamics of hematological and iron metabolism parameters in patients with chronic heart failure of ischemic etiology and iron deficiency anemia treated with intravenous ferric carboxymaltose (FCM), with special attention to the impact of concomitant depressive and anxiety symptoms. Materials and methods. A prospective observational study was conducted on 57 patients with CHF of ischemic etiology and laboratory-confirmed iron deficiency anemia. All patients received standard CHF therapy and intravenous FCM. Sertraline was added to 23 patients with clinically significant depressive and anxiety symptoms. Hematological parameters, iron parameters, quality of life and psychometric parameters (PHQ-9, GAD-7, SAQ) were assessed at baseline, day 160, and day 340. Results. Treatment resulted in significant improvements in hemoglobin, ferritin, transferrin saturation and red blood cell count in the cohort. In the subgroup with depressive/anxiety symptoms, improvements were more pronounced: hemoglobin levels increased from 111.6 (106.0; 126.4) g/L to 140.9 (125.7; 156.0) g/L at day 160 and 142.1 (128.5; 159.2) g/L at day 340, while ferritin levels increased from 52.7 (47.5; 59.0) μg/L to 103.8 (90.6; 111.0) μg/L and 116.0 (101.2; 123.9) μg/L, respectively. Depression and anxiety scores (PHQ-9, GAD-7) decreased significantly, which was accompanied by improvements in quality-of-life scores. Conclusions. Intravenous administration of FCM effectively corrects iron deficiency anemia in patients with CHF of ischemic etiology, resulting in sustained improvements in hematological and clinical parameters. Patients with comorbid depression and anxiety demonstrated more pronounced benefits, likely due to the combined effect of anemia correction and psychotropic support with sertraline. These results support a multidisciplinary approach that integrates cardiological and psychosocial care in the management of CHF.
- Open Access
- 4 April 2026
- Published by Ivano-Frankivsk National Medical University in Art of Medicine
- p. 84-92
РОЛЬ НОВОГО НУТРИЦЕВТИЧНОГО КОМПЛЕКСУ В ОПТИМІЗАЦІЇ МЕДИКАМЕНТОЗНОЇ ТЕРАПІЇ ІШЕМІЧНОЇ ХВОРОБИ СЕРЦЯ/ХРОНІЧНОГО КОРОНАРНОГО СИНДРОМУ З АРТЕРІАЛЬНОЮ ГІПЕРТЕНЗІЄЮ ТА ДИСЛІПІДЕМІЄЮ
The problem of treating stable angina, as the most common clinical form of coronary artery disease and chronic coronary syndrome (CHS), lies in the difficulty of selecting a complex of antianginal drugs due to co-, polymorbidity, side effects, and the uncertainty of the root cause of the disease in a particular patient. All of the above makes it difficult to prescribe effective up stream therapy. Meanwhile, many of the above problems could be avoided by adding modern nutraceutical complexes recommended by relevant studies to the classic personalized therapy regimen. Among the most attractive, in our opinion, is the complex recently introduced to the pharmaceutical market of Ukraine, which includes: DHA 400mg + Policonasol 20mg) – “Cardionevrin Forte” [10]. The aim of the study was to analyze the effect of the new nutraceutical complex "Cardioneurin Forte" on cardiodynamics and lipid metabolism indicators and to develop recommendations for its inclusion in the treatment of CHD/CHD-stable angina with arterial hypertension and dyslipidemia. In this study, the therapeutic efficacy of the nutraceutical complex "Cardioneurin Forte" was compared with the control group by the dynamics of lipid spectrum indicators referring to data, obtained in the study of the nutraceutical complex "Cardioneurin" [17]. A total of 90 patients participated in the two studies. In the previous study (n = 60), the therapeutic efficacy and safety of the nutraceutical complex with a policosanol content of 10 mg was evaluated, while in the last study (n = 30) the efficacy of the new nutraceutical complex was studied, in which the dose of policosanol was doubled - to 20 mg. The nutraceutical complex "Cardioneurin Forte" enhances antianginal, antihypertensive properties and hemodynamic characteristics and effectively improves the dynamics of lipid metabolism in patients with coronary artery disease/chronic ischemic heart disease - stable angina. Conclusions. Strengthening of the antianginal and antihypertensive properties of standard drug pharmacotherapy with adding of the nutraceutical complex "Cardioneurin Forte" is characterized by increased physical activity, decreased shortness of breath, palpitations in comparison with the less pronounced dynamics of these clinical signs in the control group in the same direction, as well as more pronounced in the main group (standard treatment in combination with the studied nutraceutical complex) step-by-step antihypertensive therapy. Improvement of biomechanics of systolic and diastolic functions of the left ventricle according to Echocardiography and Speckle Tracking EchoCG data is more pronounced when adding the nutraceutical complex "Cardioneurin Forte" to the standard therapy of CHD/CHD-stable angina pectoris FC III. The lipid-lowering effect of the studied nutraceutical complex is not a replacement for pharmaceutical hypolipidemic drugs (statin therapy/bempedoic acid, ezetimibe, PCSK-9 inhibitors, inclisiran), but a significant addition to the standard treatment of CHD/CHD-stable angina pectoris with arterial hypertension and dyslipidemia. The positive effect of the recommended combination therapy is due to an increase in HDL-C levels, a decrease in non-HDL-C, LDL-C, and triacylglycerols in the presence of hypercholesterolemia and hypertriacylglycerolemia.
- 4 April 2026
- Published by Ivano-Frankivsk National Medical University in Art of Medicine
- p. 84-92
Open AccessРОЛЬ НОВОГО НУТРИЦЕВТИЧНОГО КОМПЛЕКСУ В ОПТИМІЗАЦІЇ МЕДИКАМЕНТОЗНОЇ ТЕРАПІЇ ІШЕМІЧНОЇ ХВОРОБИ СЕРЦЯ/ХРОНІЧНОГО КОРОНАРНОГО СИНДРОМУ З АРТЕРІАЛЬНОЮ ГІПЕРТЕНЗІЄЮ ТА ДИСЛІПІДЕМІЄЮ
The problem of treating stable angina, as the most common clinical form of coronary artery disease and chronic coronary syndrome (CHS), lies in the difficulty of selecting a complex of antianginal drugs due to co-, polymorbidity, side effects, and the uncertainty of the root cause of the disease in a particular patient. All of the above makes it difficult to prescribe effective up stream therapy. Meanwhile, many of the above problems could be avoided by adding modern nutraceutical complexes recommended by relevant studies to the classic personalized therapy regimen. Among the most attractive, in our opinion, is the complex recently introduced to the pharmaceutical market of Ukraine, which includes: DHA 400mg + Policonasol 20mg) – “Cardionevrin Forte” [10]. The aim of the study was to analyze the effect of the new nutraceutical complex "Cardioneurin Forte" on cardiodynamics and lipid metabolism indicators and to develop recommendations for its inclusion in the treatment of CHD/CHD-stable angina with arterial hypertension and dyslipidemia. In this study, the therapeutic efficacy of the nutraceutical complex "Cardioneurin Forte" was compared with the control group by the dynamics of lipid spectrum indicators referring to data, obtained in the study of the nutraceutical complex "Cardioneurin" [17]. A total of 90 patients participated in the two studies. In the previous study (n = 60), the therapeutic efficacy and safety of the nutraceutical complex with a policosanol content of 10 mg was evaluated, while in the last study (n = 30) the efficacy of the new nutraceutical complex was studied, in which the dose of policosanol was doubled - to 20 mg. The nutraceutical complex "Cardioneurin Forte" enhances antianginal, antihypertensive properties and hemodynamic characteristics and effectively improves the dynamics of lipid metabolism in patients with coronary artery disease/chronic ischemic heart disease - stable angina. Conclusions. Strengthening of the antianginal and antihypertensive properties of standard drug pharmacotherapy with adding of the nutraceutical complex "Cardioneurin Forte" is characterized by increased physical activity, decreased shortness of breath, palpitations in comparison with the less pronounced dynamics of these clinical signs in the control group in the same direction, as well as more pronounced in the main group (standard treatment in combination with the studied nutraceutical complex) step-by-step antihypertensive therapy. Improvement of biomechanics of systolic and diastolic functions of the left ventricle according to Echocardiography and Speckle Tracking EchoCG data is more pronounced when adding the nutraceutical complex "Cardioneurin Forte" to the standard therapy of CHD/CHD-stable angina pectoris FC III. The lipid-lowering effect of the studied nutraceutical complex is not a replacement for pharmaceutical hypolipidemic drugs (statin therapy/bempedoic acid, ezetimibe, PCSK-9 inhibitors, inclisiran), but a significant addition to the standard treatment of CHD/CHD-stable angina pectoris with arterial hypertension and dyslipidemia. The positive effect of the recommended combination therapy is due to an increase in HDL-C levels, a decrease in non-HDL-C, LDL-C, and triacylglycerols in the presence of hypercholesterolemia and hypertriacylglycerolemia.
- Open Access
- 1 November 2025
- Published by Taylor & Francis in International Medical Case Reports Journal
- Vol. ume 18, 1457-1464
Blocked Atrial Bigeminy as an Unusual Cause of Bradycardia: A Case Report
The diagnosis of blocked atrial bigeminy may be challenging. It can easily be misinterpreted as sinus bradycardia or sinus exit block leading to unnecessary pacemaker implantation. We report a case of frequent blocked premature atrial contractions leading to episodes of marked bradycardia. A 66-year-old man disturbed with low pulse (42 bpm) measured by an automated blood pressure monitor sought medical attention. The patient also had untreated grade I arterial hypertension. Ambulatory ECG monitoring was performed and very frequent blocked premature atrial contractions were seen. The P wave of the atrial premature atrial contractions was always superimposed on the ST segment or T wave simulating a bifid T wave. Blocked atrial quadrigeminy, blocked atrial trigeminy, and blocked atrial bigeminy were observed. The minimum heart rate associated with blocked atrial bigeminy was 37 bpm. There were multiple episodes of regular ventricular rhythm during blocked atrial bigeminy. NT-proBNP concentration was within normal limits. Echocardiography showed only mild left ventricular hypertrophy, mild left atrial dilation and type I diastolic dysfunction. Therapy with flecainide and amiodarone separately was not effective. Option of radiofrequency catheter ablation was discussed with the patient, but was not accepted due to procedural risks and absence of severe symptoms related to blocked PACs. The patient was reassured and regular follow-up was recommended. The target values of blood pressure were achieved with candesartan at a dose of 32 mg. Thus, blocked atrial bigeminy is a rare cause of bradycardia with a regular ventricular rhythm. Recognition of the P wave superimposed on the ST segment or the T wave may be a clue for a correct diagnosis. Physicians should be aware of this condition to avoid unnecessary pacemaker implantation.
- 1 November 2025
- Published by Taylor & Francis in International Medical Case Reports Journal
- Vol. ume 18, 1457-1464
Open AccessBlocked Atrial Bigeminy as an Unusual Cause of Bradycardia: A Case Report
The diagnosis of blocked atrial bigeminy may be challenging. It can easily be misinterpreted as sinus bradycardia or sinus exit block leading to unnecessary pacemaker implantation. We report a case of frequent blocked premature atrial contractions leading to episodes of marked bradycardia. A 66-year-old man disturbed with low pulse (42 bpm) measured by an automated blood pressure monitor sought medical attention. The patient also had untreated grade I arterial hypertension. Ambulatory ECG monitoring was performed and very frequent blocked premature atrial contractions were seen. The P wave of the atrial premature atrial contractions was always superimposed on the ST segment or T wave simulating a bifid T wave. Blocked atrial quadrigeminy, blocked atrial trigeminy, and blocked atrial bigeminy were observed. The minimum heart rate associated with blocked atrial bigeminy was 37 bpm. There were multiple episodes of regular ventricular rhythm during blocked atrial bigeminy. NT-proBNP concentration was within normal limits. Echocardiography showed only mild left ventricular hypertrophy, mild left atrial dilation and type I diastolic dysfunction. Therapy with flecainide and amiodarone separately was not effective. Option of radiofrequency catheter ablation was discussed with the patient, but was not accepted due to procedural risks and absence of severe symptoms related to blocked PACs. The patient was reassured and regular follow-up was recommended. The target values of blood pressure were achieved with candesartan at a dose of 32 mg. Thus, blocked atrial bigeminy is a rare cause of bradycardia with a regular ventricular rhythm. Recognition of the P wave superimposed on the ST segment or the T wave may be a clue for a correct diagnosis. Physicians should be aware of this condition to avoid unnecessary pacemaker implantation.
- Open Access
- 1 September 2025
- Published by Ordem dos Medicos in Acta Medica Portuguesa
- Vol. 38 (9) , 597-598
Atrial Fibrillation Patterns on Ambulatory Electrocardiogram Monitoring and Risk of Stroke
- 1 September 2025
- Published by Ordem dos Medicos in Acta Medica Portuguesa
- Vol. 38 (9) , 597-598
Open AccessAtrial Fibrillation Patterns on Ambulatory Electrocardiogram Monitoring and Risk of Stroke
- Open Access
- 10 December 2023
- Published by Ivano-Frankivsk National Medical University in Art of Medicine
- p. 10-16
sST 2 AS A MARKER OF THE TREATMENT OF PATIENTS AFTER MYOCARDIAL INFARCTION WITH ACCOMPANYING ARTERIAL HYPERTENSION ON THE BACKGROUND OF TREATMENT WITH MELDONIUM AND FOLIC ACID
Ішемічна хвороба серця (ІХС) є однією з основних причин смертності в Україні та в усьому світі. Артеріальна гіпертензія (АГ) є найбільш поширеним керованим фактором серцево-судинної захворюваності. sST2 — це сучасний маркер кардіофіброзу, який може допомогти оцінити ефективність основного лікування пацієнтів з ІХС та супутньою АГ. Мета. Вивчити можливість застосування sST2 як маркера ефективності лікування пацієнтів після перенесеного інфаркту міокарда із супутньою артеріальною гіпертензією на фоні лікування мельдонієм і фолієвою кислотою. Матеріали та методи. Обстежено 40 пацієнтів із СІХС ФК ІІ-ІІІ та супутньою АГ ІІІ стадії після гострого інфаркту міокарда та ургентного стентування. Хворих було поділено на 2 групи по 20 пацієнтів: ті, які отримували стандартне лікування, і ті, які, окрім стандартного лікування, отримували комбінацію фолієвої кислоти і мельдонію. У процесі дослідження ми провели аналіз результатів загальноклінічних, лабораторних та інструментальних методів обстеження. Лабораторне дослідження рівнів sST2 у плазмі крові проводили шляхом кількісного імуноферментного аналізу. Показники серцевої гемодинаміки визначали методом ЕхоКГ. Результати. Спостерігалося покращення всіх показників ЕхоКГ у пацієнтів обох груп. Більш суттєві зміни зафіксовано стосовно КСР лівого шлуночка. Також спостерігалася інша тенденція щодо динаміки товщини задньої стінки ЛШ у систолу. У 1-й групі зниження цього показника становило 5,7% (p>0,05), а в 2-й групі ‑ 26,9% (pВисновки. Встановлено доцільність використання sST2 як маркера ефективності лікування хворих після інфаркту міокарда із супутньою АГ на фоні лікування мельдонієм і фолієвою кислотою. Застосування цитопротекторів достовірно знижувало концентрацію sST2, що робить доцільним їх використання у комплексному лікуванні хворих після перенесеного ІМ із супутньою АГ.
- 10 December 2023
- Published by Ivano-Frankivsk National Medical University in Art of Medicine
- p. 10-16
Open AccesssST 2 AS A MARKER OF THE TREATMENT OF PATIENTS AFTER MYOCARDIAL INFARCTION WITH ACCOMPANYING ARTERIAL HYPERTENSION ON THE BACKGROUND OF TREATMENT WITH MELDONIUM AND FOLIC ACID
Ішемічна хвороба серця (ІХС) є однією з основних причин смертності в Україні та в усьому світі. Артеріальна гіпертензія (АГ) є найбільш поширеним керованим фактором серцево-судинної захворюваності. sST2 — це сучасний маркер кардіофіброзу, який може допомогти оцінити ефективність основного лікування пацієнтів з ІХС та супутньою АГ. Мета. Вивчити можливість застосування sST2 як маркера ефективності лікування пацієнтів після перенесеного інфаркту міокарда із супутньою артеріальною гіпертензією на фоні лікування мельдонієм і фолієвою кислотою. Матеріали та методи. Обстежено 40 пацієнтів із СІХС ФК ІІ-ІІІ та супутньою АГ ІІІ стадії після гострого інфаркту міокарда та ургентного стентування. Хворих було поділено на 2 групи по 20 пацієнтів: ті, які отримували стандартне лікування, і ті, які, окрім стандартного лікування, отримували комбінацію фолієвої кислоти і мельдонію. У процесі дослідження ми провели аналіз результатів загальноклінічних, лабораторних та інструментальних методів обстеження. Лабораторне дослідження рівнів sST2 у плазмі крові проводили шляхом кількісного імуноферментного аналізу. Показники серцевої гемодинаміки визначали методом ЕхоКГ. Результати. Спостерігалося покращення всіх показників ЕхоКГ у пацієнтів обох груп. Більш суттєві зміни зафіксовано стосовно КСР лівого шлуночка. Також спостерігалася інша тенденція щодо динаміки товщини задньої стінки ЛШ у систолу. У 1-й групі зниження цього показника становило 5,7% (p>0,05), а в 2-й групі ‑ 26,9% (pВисновки. Встановлено доцільність використання sST2 як маркера ефективності лікування хворих після інфаркту міокарда із супутньою АГ на фоні лікування мельдонієм і фолієвою кислотою. Застосування цитопротекторів достовірно знижувало концентрацію sST2, що робить доцільним їх використання у комплексному лікуванні хворих після перенесеного ІМ із супутньою АГ.
- Open Access
- 12 April 2023
- Published by Ivano-Frankivsk National Medical University in Art of Medicine
- p. 66-70
PECULIARITIES OF CONNECTIVE TISSUE METABOLISM IN PATIENTS WITH POST-INFARCTION REMODELING AND REPERFUSION SYNDROME
Early restoration of coronary blood flow in acute myocardial infarction with elevation helps reduce the area of myocardial necrosis, prevent dilatation of the ventricular cavity, and reduce the development of arrhythmias and mortality. However, despite modern technologies in STEMI treatment, the development of reperfusion syndrome, in particular, arrhythmias, is possible after the restoration of blood flow in the infarct-related artery, which is a consequence of acute cellular, metabolic and local electrophysiological changes in the myocardium. The aim: is to investigate the long-term effects of reperfusion syndrome on the catabolic/anabolic activity of connective tissue and the processes of connective tissue framework formation in the post-infarction period in patients with myocardial infarction. Materials and methods. The study involved 156 patients with acute myocardial infarction with ST segment elevation (STEMI), and 15 apparently healthy individuals (control of laboratory parameters). The average age of the patients was (57.8±1.2) years. The percent of male patients prevailed (76 %). All MI patients were divided into two groups: Group I (98 people) – MI patients without clinical signs of reperfusion syndrome during revascularization, Group II (58 people) – MI patients with the signs of reperfusion syndrome in the form of rhythm and conductivity disturbances during revascularization of coronary arteries by percutaneous coronarography intervention (PCI) with prolonged stenting of the infarct-dependent coronary artery. Peculiarities of connective tissue metabolism were studied by the content of free and bound oxyproline, glycosaminoglycans, and antibodies to atypical collagens (Ig M and Ig G) in blood serum. Results. The recovery period after myocardial infarction showed an increase in collagen catabolism over collagen synthesizing processes in patients with MI who had reperfusion syndrome. The described patterns were also established by changes in glycosaminoglycans. The study showed an increase in the level of antibodies to atypical collagens. Particularly, the level of Ig M, which was within the norm (0.43±0.18) ng/ml, in patients with MI without reperfusion manifestations was three times higher (p<0.001), and in cases of combination of MI and reperfusion syndrome – the highest (p<0.001). Conclusions: Changes in collagen-synthesizing processes are observed in patients with MI, with a tendency to increase the processes of catabolism of the connective tissue matrix. The presence of reperfusion syndrome manifestations in MI patients after revascularization aggravates the processes of catabolism, even in the recovery period after MI. Increase in the activity of catabolic processes stimulates fibrosis and formation of rigid matrix and atypical collagen, to which antibodies are synthesized, thus blocking the pathological circuit of restructuring of the heart connective tissue framework, and accordingly its pathological remodeling. The obtained study results contribute to the identification of more sophisticated approaches to revascularization techniques to avoid negative effects of reperfusion syndrome, as well as new effective medications for collagen synthesis correction, which can increase the effectiveness of rehabilitative management of such Early restoration of coronary blood flow in acute myocardial infarction with elevation helps reduce the area of myocardial necrosis, prevent dilatation of the ventricular cavity, and reduce the development of arrhythmias and mortality. However, despite modern technologies in STEMI treatment, the development of reperfusion syndrome, in particular, arrhythmias, is possible after the restoration of blood flow in the infarct-related artery, which is a consequence of acute cellular, metabolic and local electrophysiological changes in the myocardium. The aim: is to investigate the long-term effects of reperfusion syndrome on the catabolic/anabolic activity of connective tissue and the processes of connective tissue framework formation in the post-infarction period in patients with myocardial infarction. Materials and methods. The study involved 156 patients with acute myocardial infarction with ST segment elevation (STEMI), and 15 apparently healthy individuals (control of laboratory parameters). The average age of the patients was (57.8±1.2) years. The percent of male patients prevailed (76 %). All MI patients were divided into two groups: Group I (98 people) – MI patients without clinical signs of reperfusion syndrome during revascularization, Group II (58 people) – MI patients with the signs of reperfusion syndrome in the form of rhythm and conductivity disturbances during revascularization of coronary arteries by percutaneous coronarography intervention (PCI) with prolonged stenting of the infarct-dependent coronary artery. Peculiarities of connective tissue metabolism were studied by the content of free and bound oxyproline, glycosaminoglycans, and antibodies to atypical collagens (Ig M and Ig G) in blood serum. Results. The recovery period after myocardial infarction showed an increase in collagen catabolism over collagen synthesizing processes in patients with MI who had reperfusion syndrome. The described patterns were also established by changes in glycosaminoglycans. The study showed an increase in the level of antibodies to atypical collagens. Particularly, the level of Ig M, which was within the norm (0.43±0.18) ng/ml, in patients with MI without reperfusion manifestations was three times higher (p<0.001), and in cases of combination of MI and reperfusion syndrome – the highest (p<0.001). Conclusions: Changes in collagen-synthesizing processes are observed in patients with MI, with a tendency to increase the processes of catabolism of the connective tissue matrix. The presence of reperfusion syndrome manifestations in MI patients after revascularization aggravates the...
- 12 April 2023
- Published by Ivano-Frankivsk National Medical University in Art of Medicine
- p. 66-70
Open AccessPECULIARITIES OF CONNECTIVE TISSUE METABOLISM IN PATIENTS WITH POST-INFARCTION REMODELING AND REPERFUSION SYNDROME
Early restoration of coronary blood flow in acute myocardial infarction with elevation helps reduce the area of myocardial necrosis, prevent dilatation of the ventricular cavity, and reduce the development of arrhythmias and mortality. However, despite modern technologies in STEMI treatment, the development of reperfusion syndrome, in particular, arrhythmias, is possible after the restoration of blood flow in the infarct-related artery, which is a consequence of acute cellular, metabolic and local electrophysiological changes in the myocardium. The aim: is to investigate the long-term effects of reperfusion syndrome on the catabolic/anabolic activity of connective tissue and the processes of connective tissue framework formation in the post-infarction period in patients with myocardial infarction. Materials and methods. The study involved 156 patients with acute myocardial infarction with ST segment elevation (STEMI), and 15 apparently healthy individuals (control of laboratory parameters). The average age of the patients was (57.8±1.2) years. The percent of male patients prevailed (76 %). All MI patients were divided into two groups: Group I (98 people) – MI patients without clinical signs of reperfusion syndrome during revascularization, Group II (58 people) – MI patients with the signs of reperfusion syndrome in the form of rhythm and conductivity disturbances during revascularization of coronary arteries by percutaneous coronarography intervention (PCI) with prolonged stenting of the infarct-dependent coronary artery. Peculiarities of connective tissue metabolism were studied by the content of free and bound oxyproline, glycosaminoglycans, and antibodies to atypical collagens (Ig M and Ig G) in blood serum. Results. The recovery period after myocardial infarction showed an increase in collagen catabolism over collagen synthesizing processes in patients with MI who had reperfusion syndrome. The described patterns were also established by changes in glycosaminoglycans. The study showed an increase in the level of antibodies to atypical collagens. Particularly, the level of Ig M, which was within the norm (0.43±0.18) ng/ml, in patients with MI without reperfusion manifestations was three times higher (p<0.001), and in cases of combination of MI and reperfusion syndrome – the highest (p<0.001). Conclusions: Changes in collagen-synthesizing processes are observed in patients with MI, with a tendency to increase the processes of catabolism of the connective tissue matrix. The presence of reperfusion syndrome manifestations in MI patients after revascularization aggravates the processes of catabolism, even in the recovery period after MI. Increase in the activity of catabolic processes stimulates fibrosis and formation of rigid matrix and atypical collagen, to which antibodies are synthesized, thus blocking the pathological circuit of restructuring of the heart connective tissue framework, and accordingly its pathological remodeling. The obtained study results contribute to the identification of more sophisticated approaches to revascularization techniques to avoid negative effects of reperfusion syndrome, as well as new effective medications for collagen synthesis correction, which can increase the effectiveness of rehabilitative management of such Early restoration of coronary blood flow in acute myocardial infarction with elevation helps reduce the area of myocardial necrosis, prevent dilatation of the ventricular cavity, and reduce the development of arrhythmias and mortality. However, despite modern technologies in STEMI treatment, the development of reperfusion syndrome, in particular, arrhythmias, is possible after the restoration of blood flow in the infarct-related artery, which is a consequence of acute cellular, metabolic and local electrophysiological changes in the myocardium. The aim: is to investigate the long-term effects of reperfusion syndrome on the catabolic/anabolic activity of connective tissue and the processes of connective tissue framework formation in the post-infarction period in patients with myocardial infarction. Materials and methods. The study involved 156 patients with acute myocardial infarction with ST segment elevation (STEMI), and 15 apparently healthy individuals (control of laboratory parameters). The average age of the patients was (57.8±1.2) years. The percent of male patients prevailed (76 %). All MI patients were divided into two groups: Group I (98 people) – MI patients without clinical signs of reperfusion syndrome during revascularization, Group II (58 people) – MI patients with the signs of reperfusion syndrome in the form of rhythm and conductivity disturbances during revascularization of coronary arteries by percutaneous coronarography intervention (PCI) with prolonged stenting of the infarct-dependent coronary artery. Peculiarities of connective tissue metabolism were studied by the content of free and bound oxyproline, glycosaminoglycans, and antibodies to atypical collagens (Ig M and Ig G) in blood serum. Results. The recovery period after myocardial infarction showed an increase in collagen catabolism over collagen synthesizing processes in patients with MI who had reperfusion syndrome. The described patterns were also established by changes in glycosaminoglycans. The study showed an increase in the level of antibodies to atypical collagens. Particularly, the level of Ig M, which was within the norm (0.43±0.18) ng/ml, in patients with MI without reperfusion manifestations was three times higher (p<0.001), and in cases of combination of MI and reperfusion syndrome – the highest (p<0.001). Conclusions: Changes in collagen-synthesizing processes are observed in patients with MI, with a tendency to increase the processes of catabolism of the connective tissue matrix. The presence of reperfusion syndrome manifestations in MI patients after revascularization aggravates the...
- Open Access
- 16 November 2021
- Published by LLC Publishing house Medknyha in Терапевтика
- Vol. 2 (3) , 27-33
Варіабельність серцевого ритму в постінфарктних хворих із серцевою недостатністю
Дослідження варіабельності ритму серця (ВРС) — один із найбільш надійних методів для прогнозу тривалості життя пацієнтів після перенесеного ІМ із серцевою недостатністю. Динаміка показників ВРС при добовому моніторуванні ЕКГ дозволяє спрогнозувати підвищений ризик раптової смерті, шлуночкові аритмії, частоту серцевих скорочень (ЧСС), ішемію міокарда та зміни інтервалу Q-T. Мета роботи — встановити особливості ВСР у пацієнтів із повторними інфарктами міокарда і серцевою недостатністю. Матеріали та методи. Обстежено 160 хворих із гострим повторним інфарктом міокарда та СН ІІ-ІІІ ФК. Дослідження варіабельності серцевого ритму проводили за 5-хвилинною реєстрацією за допомогою системи «Кардіолаб» виробництва фірми «ХАИ-МЕДИКА» (м. Харків, Україна). Результати та обговорення. Аналіз ВСР в обстежених пацієнтів залежно від кількості перенесених ІМ в анамнезі показав, що на момент госпіталізації спостерігається зниження вегетативного тонусу з переважанням симпатичної нервової системи. Зокрема, співвідношення LF/HF становило (1,65±0,2) ум. од. у хворих основної групи з повторним ІМ (2,45±0,9) ум. од. (p<0,0001), а третинним — (3,5±0,25) ум. од. (p6 років (2,89±0,18) ум. од. в основній групі (р<0,001) проти (1,65±0,2) ум. од. у здорових осіб. Типи діастолічної дисфункції істотно не впливали на ВСР. Висновки. Отже, згідно з аналізом показників варіабельності серцевого ритму, у всіх пацієнтів із повторними ІМ та СН, незалежно від кількості перенесених ІМ, стадії, тривалості СН та типу дисфункції лівого шлуночка, переважали симпатичні впливи на серце. Усі запропоновані схеми лікування приводили до достовірного покращення загальної ВСР, про що свідчить тенденція до зниження LF/HF. During the stratification of risk for patients after myocardial infarction (MI), assessment of autonomic imbalance plays an important role. Heart rate variability (HRV) after MI has important prognostic value regarding the prediction of overall mortality of patients, identify patients at risk for symptomatic sustained ventricular tachycardia, evaluation of the clinical course of heart failure and its prognosis. Purpose. Set features of HRV in patients with recurrent myocardial infarction according to Halter-ECG monitoring. Materials and methods. The study involved 160 patients with recurrent myocardial infarction with heart failure who have made a major group and 15 patients without recurrent myocardial infarction with heart failure (control group). Investigation of heart rate variability was performed on a 5-minute recording with the help of CARDIOLAB the product of the company HAI-MEDICA (Kharkiv, Ukraine). Results and discussion. The analysis of HRV in examined patients, depending on the amount of carried over MI in history showed that at the time of hospitalization is a decrease in autonomic tone with predominance of the sympathetic nervous system. In particular, the LF/HF ratio in the normal sense of (1.65±0.2) st. un. in patients of the main group with recurrent MI was (2.45±0.9) st. un. (p<0.0001), and the tertiary (3.5±0.25) st. un. (p<0.0001). Patients in the control group had LF/HF ratio (1.48±0.08) st. un. (p6 years (2.89±0.18) st. un. in the study group (p<0.0001) versus (1.65±0.2) st.n. in healthy individuals. During the systolic and diastolic dysfunction, key changes in parameters of HRV were monosemantic: SDNN-reduced, and LF/HF-enhanced. Types of diastolic dysfunction did not significantly affect the HRV. Conclusions. So, in all patients with recurrent myocardial infarction, regardless of the number of carried over MI, stage or duration of heart failure and type of dysfunction of the left ventricle, prevailed sympathetic effects on the heart, according to the analysis of heart rate variability. All treatment methods resulted in a significant improvement in overall heart rate variability, as evidenced by a downward trend in LF/HF.
- 16 November 2021
- Published by LLC Publishing house Medknyha in Терапевтика
- Vol. 2 (3) , 27-33
Open AccessВаріабельність серцевого ритму в постінфарктних хворих із серцевою недостатністю
Дослідження варіабельності ритму серця (ВРС) — один із найбільш надійних методів для прогнозу тривалості життя пацієнтів після перенесеного ІМ із серцевою недостатністю. Динаміка показників ВРС при добовому моніторуванні ЕКГ дозволяє спрогнозувати підвищений ризик раптової смерті, шлуночкові аритмії, частоту серцевих скорочень (ЧСС), ішемію міокарда та зміни інтервалу Q-T. Мета роботи — встановити особливості ВСР у пацієнтів із повторними інфарктами міокарда і серцевою недостатністю. Матеріали та методи. Обстежено 160 хворих із гострим повторним інфарктом міокарда та СН ІІ-ІІІ ФК. Дослідження варіабельності серцевого ритму проводили за 5-хвилинною реєстрацією за допомогою системи «Кардіолаб» виробництва фірми «ХАИ-МЕДИКА» (м. Харків, Україна). Результати та обговорення. Аналіз ВСР в обстежених пацієнтів залежно від кількості перенесених ІМ в анамнезі показав, що на момент госпіталізації спостерігається зниження вегетативного тонусу з переважанням симпатичної нервової системи. Зокрема, співвідношення LF/HF становило (1,65±0,2) ум. од. у хворих основної групи з повторним ІМ (2,45±0,9) ум. од. (p<0,0001), а третинним — (3,5±0,25) ум. од. (p6 років (2,89±0,18) ум. од. в основній групі (р<0,001) проти (1,65±0,2) ум. од. у здорових осіб. Типи діастолічної дисфункції істотно не впливали на ВСР. Висновки. Отже, згідно з аналізом показників варіабельності серцевого ритму, у всіх пацієнтів із повторними ІМ та СН, незалежно від кількості перенесених ІМ, стадії, тривалості СН та типу дисфункції лівого шлуночка, переважали симпатичні впливи на серце. Усі запропоновані схеми лікування приводили до достовірного покращення загальної ВСР, про що свідчить тенденція до зниження LF/HF. During the stratification of risk for patients after myocardial infarction (MI), assessment of autonomic imbalance plays an important role. Heart rate variability (HRV) after MI has important prognostic value regarding the prediction of overall mortality of patients, identify patients at risk for symptomatic sustained ventricular tachycardia, evaluation of the clinical course of heart failure and its prognosis. Purpose. Set features of HRV in patients with recurrent myocardial infarction according to Halter-ECG monitoring. Materials and methods. The study involved 160 patients with recurrent myocardial infarction with heart failure who have made a major group and 15 patients without recurrent myocardial infarction with heart failure (control group). Investigation of heart rate variability was performed on a 5-minute recording with the help of CARDIOLAB the product of the company HAI-MEDICA (Kharkiv, Ukraine). Results and discussion. The analysis of HRV in examined patients, depending on the amount of carried over MI in history showed that at the time of hospitalization is a decrease in autonomic tone with predominance of the sympathetic nervous system. In particular, the LF/HF ratio in the normal sense of (1.65±0.2) st. un. in patients of the main group with recurrent MI was (2.45±0.9) st. un. (p<0.0001), and the tertiary (3.5±0.25) st. un. (p<0.0001). Patients in the control group had LF/HF ratio (1.48±0.08) st. un. (p6 years (2.89±0.18) st. un. in the study group (p<0.0001) versus (1.65±0.2) st.n. in healthy individuals. During the systolic and diastolic dysfunction, key changes in parameters of HRV were monosemantic: SDNN-reduced, and LF/HF-enhanced. Types of diastolic dysfunction did not significantly affect the HRV. Conclusions. So, in all patients with recurrent myocardial infarction, regardless of the number of carried over MI, stage or duration of heart failure and type of dysfunction of the left ventricle, prevailed sympathetic effects on the heart, according to the analysis of heart rate variability. All treatment methods resulted in a significant improvement in overall heart rate variability, as evidenced by a downward trend in LF/HF.
- Open Access
- 7 October 2021
- Published by Ivano-Frankivsk National Medical University in Art of Medicine
- p. 69-80
MANAGEMENT OF PATIENTS WITH DYSLIPIDEMIA IN THE PRACTICE OF FAMILY MEDICINE
Dyslipidemia is an important problem for family doctors, as it is a risk factor for the development of atherosclerotic cardiovascular diseases (ACVD). ACVD is the cause of more than 4 million deaths in Europe today. Women in this sad statistic are 2.2 million, and men - 1.8 million. It is expected, that mortality due to cardiovascular diseases in men aged up to 65 years is significantly higher than in women (430 thousand and 193 thousand, respectively). The ESC/EAS-2019 (European Society of Cardiology / European Society of Atherosclerosis) updated guidelines on the management of people with dyslipidemia (DLP) provide specific recommendations that can be used by family doctors in Ukraine in their daily preventive and curative work. The ESC/EAS-2019 (European Society of Cardiology / European Society of Atherosclerosis) and the Ukrainian Society of Atherosclerosis (USA) guidelines emphasize that the cornerstone of the prevention and treatment of ACVD is primarily the detection and correction of DLP. The prevalence of DLP in Ukraine is about 20%. At the same time, for effective correction of DLP it is important to verify the type of dyslipidemia, isolate genetically determined forms of dyslipidemia (familial hypercholesterolemia), establish cardiovascular risk, select the most effective measures of lifestyle modification and formulate therapeutic goals of prevention / treatment. In the treatment of DLP apart from lifestyle modification, the drugs of choice are statins in high-intensity doses. Ezetimibe and PCSK-9 inhibitors can be used in addition to statin therapy in case of its ineffectiveness or side effects. It was found, that resistance to statins and their intolerance is the basis for the use of non-statin hypolipidemic drugs (nutraceuticals), among which the most studied are ω-3 PUFA and phytosterols. The ESC / EAS (2019) guidelines state that consumption of ω-3 PUFAs is associated with a lower risk of death from CVD and stroke. It was noted, that the mechanism of reducing TG levels under the influence of ω-3 PUFA may be related to their ability to interact with PPAR (receptors that activate the proliferation of peroxisomes) and reduce the secretion of apoprotein B. Recent clinical studies confirm the need for high doses of highly purified form of ω-3 PUFA for patients with elevated TG levels, despite treatment with statins. Another non-statin drug that reduces LDL levels is bempedoic acid. Studies have shown a significant reduction in LDL levels in patients receiving additional bempedoic acid. The effectiveness of bempedoic acid as a monotherapy of DLP is now being studied. This review presents new data on the effectiveness of the combination of sugar cane extract policosanol with ω-3 PUFA (docosahexaenoic acid 10%). The drug of this composition "Cardioneurin" is present on the pharmaceutical market of Ukraine. Clinical studies have shown, that in case of resistance or intolerance to statins, especially in high doses, a hybrid strategy of lipid-lowering therapy can be used - a combination of low-intensity doses of statins with a combined nutraceutic "Cardioneurin". This treatment reduces the level of atherogenicity by 22%, which gives grounds for its use in the practice of family doctors. Other forms of policosanol (other than sugar cane), such as those derived from beeswax or wheat germ, do not have an adequate evidence base. Thus, dyslipidemia is the primary and main factor in the development of ACS, it in most cases occurs long before the emergence of other important risk factors and may even be a prerequisite for their occurrence. Epidemiological evidence suggests, for example, that DLP may in itself be a risk factor for STEMI / NSTEMI and unstable angina. Dyslipidemia is an important problem for family doctors, as it is a risk factor for the development of atherosclerotic cardiovascular diseases (ACVD). ACVD is the cause of more than 4 million deaths in Europe today. Women in this sad statistic are 2.2 million, and men - 1.8 million. It is expected, that mortality due to cardiovascular diseases in men aged up to 65 years is significantly higher than in women (430 thousand and 193 thousand, respectively). The ESC/EAS-2019 (European Society of Cardiology / European Society of Atherosclerosis) updated guidelines on the management of people with dyslipidemia (DLP) provide specific recommendations that can be used by family doctors in Ukraine in their daily preventive and curative work. The ESC/EAS-2019 (European Society of Cardiology / European Society of Atherosclerosis) and the Ukrainian Society of Atherosclerosis (USA) guidelines emphasize that the cornerstone of the prevention and treatment of ACVD is primarily the detection and correction of DLP. The prevalence of DLP in Ukraine is about 20%. At the same time, for effective correction of DLP it is important to verify the type of dyslipidemia, isolate genetically determined forms of dyslipidemia (familial hypercholesterolemia), establish cardiovascular risk, select the most effective measures of lifestyle modification and formulate therapeutic goals of prevention / treatment. In the treatment of DLP apart from lifestyle modification, the drugs of choice are statins in high-intensity doses. Ezetimibe and PCSK-9 inhibitors can be used in addition to statin therapy in case of its ineffectiveness or side effects. It was found, that resistance to statins and their intolerance is the basis for the use of non-statin hypolipidemic drugs (nutraceuticals), among which the most studied are ω-3 PUFA and phytosterols. The ESC / EAS (2019) guidelines state that consumption of ω-3 PUFAs is associated with a lower risk of death from CVD and stroke. It was noted, that the mechanism of reducing TG levels under the influence of ω-3 PUFA may be related to their ability to interact with PPAR (receptors that activate the proliferation of peroxisomes) and reduce the secretion of apoprotein B. Recent...
- 7 October 2021
- Published by Ivano-Frankivsk National Medical University in Art of Medicine
- p. 69-80
Open AccessMANAGEMENT OF PATIENTS WITH DYSLIPIDEMIA IN THE PRACTICE OF FAMILY MEDICINE
Dyslipidemia is an important problem for family doctors, as it is a risk factor for the development of atherosclerotic cardiovascular diseases (ACVD). ACVD is the cause of more than 4 million deaths in Europe today. Women in this sad statistic are 2.2 million, and men - 1.8 million. It is expected, that mortality due to cardiovascular diseases in men aged up to 65 years is significantly higher than in women (430 thousand and 193 thousand, respectively). The ESC/EAS-2019 (European Society of Cardiology / European Society of Atherosclerosis) updated guidelines on the management of people with dyslipidemia (DLP) provide specific recommendations that can be used by family doctors in Ukraine in their daily preventive and curative work. The ESC/EAS-2019 (European Society of Cardiology / European Society of Atherosclerosis) and the Ukrainian Society of Atherosclerosis (USA) guidelines emphasize that the cornerstone of the prevention and treatment of ACVD is primarily the detection and correction of DLP. The prevalence of DLP in Ukraine is about 20%. At the same time, for effective correction of DLP it is important to verify the type of dyslipidemia, isolate genetically determined forms of dyslipidemia (familial hypercholesterolemia), establish cardiovascular risk, select the most effective measures of lifestyle modification and formulate therapeutic goals of prevention / treatment. In the treatment of DLP apart from lifestyle modification, the drugs of choice are statins in high-intensity doses. Ezetimibe and PCSK-9 inhibitors can be used in addition to statin therapy in case of its ineffectiveness or side effects. It was found, that resistance to statins and their intolerance is the basis for the use of non-statin hypolipidemic drugs (nutraceuticals), among which the most studied are ω-3 PUFA and phytosterols. The ESC / EAS (2019) guidelines state that consumption of ω-3 PUFAs is associated with a lower risk of death from CVD and stroke. It was noted, that the mechanism of reducing TG levels under the influence of ω-3 PUFA may be related to their ability to interact with PPAR (receptors that activate the proliferation of peroxisomes) and reduce the secretion of apoprotein B. Recent clinical studies confirm the need for high doses of highly purified form of ω-3 PUFA for patients with elevated TG levels, despite treatment with statins. Another non-statin drug that reduces LDL levels is bempedoic acid. Studies have shown a significant reduction in LDL levels in patients receiving additional bempedoic acid. The effectiveness of bempedoic acid as a monotherapy of DLP is now being studied. This review presents new data on the effectiveness of the combination of sugar cane extract policosanol with ω-3 PUFA (docosahexaenoic acid 10%). The drug of this composition "Cardioneurin" is present on the pharmaceutical market of Ukraine. Clinical studies have shown, that in case of resistance or intolerance to statins, especially in high doses, a hybrid strategy of lipid-lowering therapy can be used - a combination of low-intensity doses of statins with a combined nutraceutic "Cardioneurin". This treatment reduces the level of atherogenicity by 22%, which gives grounds for its use in the practice of family doctors. Other forms of policosanol (other than sugar cane), such as those derived from beeswax or wheat germ, do not have an adequate evidence base. Thus, dyslipidemia is the primary and main factor in the development of ACS, it in most cases occurs long before the emergence of other important risk factors and may even be a prerequisite for their occurrence. Epidemiological evidence suggests, for example, that DLP may in itself be a risk factor for STEMI / NSTEMI and unstable angina. Dyslipidemia is an important problem for family doctors, as it is a risk factor for the development of atherosclerotic cardiovascular diseases (ACVD). ACVD is the cause of more than 4 million deaths in Europe today. Women in this sad statistic are 2.2 million, and men - 1.8 million. It is expected, that mortality due to cardiovascular diseases in men aged up to 65 years is significantly higher than in women (430 thousand and 193 thousand, respectively). The ESC/EAS-2019 (European Society of Cardiology / European Society of Atherosclerosis) updated guidelines on the management of people with dyslipidemia (DLP) provide specific recommendations that can be used by family doctors in Ukraine in their daily preventive and curative work. The ESC/EAS-2019 (European Society of Cardiology / European Society of Atherosclerosis) and the Ukrainian Society of Atherosclerosis (USA) guidelines emphasize that the cornerstone of the prevention and treatment of ACVD is primarily the detection and correction of DLP. The prevalence of DLP in Ukraine is about 20%. At the same time, for effective correction of DLP it is important to verify the type of dyslipidemia, isolate genetically determined forms of dyslipidemia (familial hypercholesterolemia), establish cardiovascular risk, select the most effective measures of lifestyle modification and formulate therapeutic goals of prevention / treatment. In the treatment of DLP apart from lifestyle modification, the drugs of choice are statins in high-intensity doses. Ezetimibe and PCSK-9 inhibitors can be used in addition to statin therapy in case of its ineffectiveness or side effects. It was found, that resistance to statins and their intolerance is the basis for the use of non-statin hypolipidemic drugs (nutraceuticals), among which the most studied are ω-3 PUFA and phytosterols. The ESC / EAS (2019) guidelines state that consumption of ω-3 PUFAs is associated with a lower risk of death from CVD and stroke. It was noted, that the mechanism of reducing TG levels under the influence of ω-3 PUFA may be related to their ability to interact with PPAR (receptors that activate the proliferation of peroxisomes) and reduce the secretion of apoprotein B. Recent...